Method for preventing secondary effects

• US 4,988,675 A
• Filed: 01/25/1989
• Issued: 01/29/1991
• Est. Priority Date: 02/05/1988
• Status: Expired due to Term

• Current Assignee: Novartis Corporation (Novartis Ag)
• Original Assignee: Ciba-Geigy Corporation (Novartis Ag)
• Inventors: Schmid, Christoph, Guler, Hans-Peter, Zapf, Jurgen, Froesch, Ernst R.
• Primary Examiner(s): Schain, Howard E.
• Assistant Examiner(s): KOH, CHOON P
• Application Number:
  US07/301,680
• Time in Patent Office: 734 Days
• Field of Search: 514/4, 514/12
• US Class Current: 514/6.5
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

The invention concerns a method for treating and preventing secondary effects of hyperinsulinemia by application of insulin-like growth factor I (IGF I), and pharmaceutical compositions comprising IGF I which are useful for this purpose.

Claims

1. A method for treating and preventing secondary effects of hyperinsulinemia in diabetics treated with insulin, characterized in that an effective amount of IGF I and a lower than normal amount of insulin is administered.

3. A method according to claim 1, characterized in that recombinant IGF I is used.

4. A method according to claim 1, characterized in that IGF I is administered in an amount of from about 24 μ

g/kg/day up to about 720 μ

g/kg/day.

5. A method according to claim 1, characterized in that in addition to IGF I insulin is administered in lower amounts than if used alone.

6. A method according to claim 1, characterized in that in addition to IGF I insulin is administered in amounts which by themselves have little effect on blood glucose.

7. A method according to claim 1, characterized in that in addition to IGF I insulin is administered in amounts of between 0.2 IU/kg/24 h up to about 0.5 IU/kg/24 h.

8. A method according to claim 1, characterized in that IGF I is subcutaneously or intravenously infused via a minipump.

9. A method according to claim 1, characterized in that IGF I is subcutaneously, intravenously or intramuscularly administered continuously in a dose of about 1 μ

g/kg/h up to about 24 μ

g/kg/h.

2. A method for treating type 2 diabetics, obese subjects or subjects with hyperlipidemia, characterized in that an effective amount of IGF I alone is administered.

10. Method for the manufacture of a pharmaceutical preparation for treating and preventing secondary effects of hyperinsulinemia in diabetics treated with insulin characterized in that IGF I and a lower than normal amount of insulin are pharmaceutically processed.